NOVT vs NVDA

Novanta Inc. exhibits exceptional financial health with a Piotroski F-Score of 8/9 and a very conservative debt profile (Debt/Equity 0.23). However, the company is severely overvalued based on deterministic metrics, with a current price of $128.85 dwarfing the Graham Number ($34.91) and Intrinsic Value ($11.61). While the earnings track record is stellar with consistent beats over 25 quarters, the massive trailing P/E of 87.65 and bearish insider selling by the CEO and CFO create significant valuation risk. The stock is currently a high-quality business trading at a speculative premium.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.